Evidence digest
What the research on GHK-Cu actually shows
The indexed literature on GHK-Cu includes human clinical or observational records (3 human-clinical or observational records, 1 in-vitro record). This digest describes the shape of that evidence and links the records behind it. It does not judge whether GHK-Cu is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 3 human · compound record
- Studies indexed
- 4
- Human evidence
- 3
- Preclinical only
- 1
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for GHK-Cu (3).
- In-vitro work is indexed for this compound.
- Published research is indexed back to 1977, with roughly 175 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether GHK-Cu is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
1 in vitro · 3 human — controlled trial
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| In vitro and formulation work on GHK-Cu in skin modelsPubMed listing | In vitro | Cultured keratinocytes and skin equivalents | — | Placeholder seed record. Cell-culture and cosmetic formulation work. Assay design for this compound must account for the copper complex; results reporting peptide purity alone do not characterise the material. | Listing |
| Effects of topical copper tripeptide complex on CO2 laser-resurfaced skinArchives of facial plastic surgery · 2006 | Human — controlled trial | Not recorded | — | To evaluate the role of skin care products that contain a copper tripeptide complex, glycyl-l-histidyl-l-lysine-Cu(2+) (GHK-Cu), in treating carbon dioxide (CO(2)) laser-resurfaced skin. Patients meeting the inclusion criteria underwent circumoral skin resurfacing using a CO(2) laser at standard settings. Patients were then randomized to receive posttreatment skin regimens with or without GHK-Cu. Evaluations for erythema throughout the posttreatment period were performed usin… | PMID 16847171 |
| A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcersJournal of vascular surgery · 1992 | Human — controlled trial | Not recorded | — | Chronic wounds such as venous stasis ulcers have become a socioeconomic problem. Even with successful initial management, the recurrence rate approaches 70%. With the advent of new wound healing agents, nonoperative attempts to heal these wounds appear indicated. This study reports a prospective randomized evaluator-blinded trial comparing two potential wound healing agents to an inert vehicle placebo. Eighty-six evaluable patients completed the trial. Silver sulfadiazine 1% … | PMID 1495150 |
| Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbitsVeterinary dermatology · 2006 | Human — controlled trial | Not recorded | — | In this study the clinical and histopathological effects of topically applied tripeptide-copper complex (TCC) and zinc oxide on open-wound healing in rabbits was evaluated. Eighteen New Zealand rabbits were divided into three groups: TCC, zinc oxide and no treatment. One full thickness wound was created on each side of the dorsal midline in each rabbit. Wound margins were traced on days 0, 7, 14, and 21 and topical TCC and zinc oxide were applied daily for 21 days to each rab… | PMID 17083573 |
Vendors listing GHK-Cu
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Curo | 93.877% | 1 | profile → |
| Next Gen Peptides | 93.897% | 3 | profile → |
| Amino Club | 90.495% | 2 | profile → |
| Ascend Science | 90.291% | 2 | profile → |
| PeptidePlugs | 89.790% | 7 | profile → |
| Hydro Research Peptides | 88.289% | 1 | profile → |
| Prime Peptides | 87.180% | 1 | profile → |
| Protide Health | 83.994% | 0 | profile → |
| American Peptides | 83.6100% | 2 | profile → |
| Origin Labs | 81.885% | 1 | profile → |
| Northline Labs | 79.493% | 2 | profile → |
| NeuroLabs Research | 79.386% | 2 | profile → |
| Koi Peptides | 79.394% | 1 | profile → |
| ZC Labs | 79.384% | 2 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 0 | profile → |
| Peptime | 75.359% | 1 | profile → |
| Modern Aminos | 74100% | 2 | profile → |
| Simple Peptide | 7489% | 2 | profile → |
| True Research Labs | 71.971% | 0 | profile → |
| GenX Peptides | 70.868% | 0 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Improved Peptides | 7089% | 1 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.